Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
The trade threats could reduce exports to the United States and dampen investment in Europe, dealing a blow to growth at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback